MedTrace Logo

Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas

NCT04197492 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2024-01-05

No results posted yet for this study

Summary

A Phase II Study of Hypofractionated Stereotactic Radiotherapy (HSRT) With Anlotinib in Patients With Recurrent High-Grade Glioma. The primary endpoint is overall survival after radiotherapy. Secondary endpoints included progress-free survival, objective response rate, cognitive function, quality of life, toxicity.

Conditions

  • Malignant Glioma

Interventions

RADIATION

Hypofractionated Stereotactic Radiotherapy

Hypofractionated stereotactic radiotherapy (CyberKnife, 25Gy/5fx)

DRUG

Anlotinib

Anlotinib once daily (12mg/d) on days 1-14 of a 21-day cycle.

Sponsors & Collaborators

  • Huashan Hospital

    lead OTHER

Principal Investigators

  • Enmin Wang, MD · Huashan Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-16
Primary Completion
2023-12-31
Completion
2024-12-31
FDA Device
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04197492 on ClinicalTrials.gov